PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).Lauren C. Harshman, David F. McDermott, Sabina Signoretti et al.|Journal of Clinical Oncology|2019Cited by 13
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).Lauren C. Harshman, Mäneka Puligandla, Naomi B. Haas et al.|Journal of Clinical Oncology|2017Cited by 12
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).Lauren C. Harshman, Mäneka Puligandla, Naomi B. Haas et al.|Journal of Clinical Oncology|2019Cited by 7
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).Lauren C. Harshman, Mäneka Puligandla, Naomi B. Haas et al.|Journal of Clinical Oncology|2018Cited by 2
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).Lauren C. Harshman, Mäneka Puligandla, Naomi B. Haas et al.|Journal of Clinical Oncology|2018Cited by 1